ReviewExpert review of clinical pharmacology2025
Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors.
Review in Expert review of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTyrosine kinase inhibitors (TKIs) have significantly improved outcomes for cancer patients. However, TKIs have a narrow therapeutic window, impact a high-risk population, and are frequently combined with additional medications, each of which increases the risk of drug-drug interactions (DDIs). As polypharmacy becomes more common, especially in older and higher-risk groups that are prescribed TKIs, there is an increased risk for harmful DDIs. AREAS COVERED: TKI-related DDIs can lead to toxicity or reduced efficacy, which worsens patient outcomes and quality of life. In this review, we utilized the Drug Interaction Database (DIDB), FDA labels, and PubMed TKI DDI/ADME queries to outline the mechanisms underlying both pharmacokinetic (PK) and pharmacodynamic (PD) DDIs with TKIs. Pharmacokinetic DDIs involve changes in the absorption, distribution, metabolism, and excretion (ADME) of a molecule (victim) caused by another drug (perpetrator). These DDIs may involve direct inhibition, post-translational modification, or transcriptional regulation. Pharmacodynamic DDIs involve overlapping mechanisms resulting in additive, synergistic, or antagonistic effects when two medications are combined. EXPERT OPINION: Understanding the mechanisms underlying DDIs facilitates a better grasp of TKI clinical pharmacology and will help in the development of strategies to optimize drug dosing and avoid DDIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.